A role for P2Y12R in inflammation and immune modulation has been recently reported (Wang et al., 2004; Diehl et al., 2010; Burnstock and Boeynaems, 2014; Cattaneo, 2015; Hechler and Gachet, 2015). Interestingly, it has been shown that platelets negatively affect the adoptive T cell therapy (ACT) in cancer by producing high levels of active TGFβ. Moreover, platelets are the only cell type known so far to constitutively express the TGFβ-docking receptor glycoprotein A repetitions predominant (GARP) which allows them to capture TGFβ from both other cells and the extracellular matrix. This platelet-specific TGFβ-GARP-axis seems to play a critical role by constraining the antitumor activity of T cell immunity (Rachidi et al., 2017). In B16-F1 melanoma-C57BL/6 mice, clopidogrel, a P2Y12R antagonist, in combination with aspirin made the ACT therapy highly effective compared to the control group, which received water. Indeed, most mice survived without relapse for more than 3 months (Rachidi et al., 2017).